Cargando…

Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial

Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Priyali, Wolever, Thomas MS., Jenkins, Alexandra L., Ezatagha, Adish, Campbell, Janice, Zurbau, Andreea, Jain, Manish, Gote, Manoj, Bhaduri, Anirban, Mullick, Ashim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102419/
https://www.ncbi.nlm.nih.gov/pubmed/33997376
http://dx.doi.org/10.1016/j.heliyon.2021.e06805
_version_ 1783689099029250048
author Shah, Priyali
Wolever, Thomas MS.
Jenkins, Alexandra L.
Ezatagha, Adish
Campbell, Janice
Zurbau, Andreea
Jain, Manish
Gote, Manoj
Bhaduri, Anirban
Mullick, Ashim
author_facet Shah, Priyali
Wolever, Thomas MS.
Jenkins, Alexandra L.
Ezatagha, Adish
Campbell, Janice
Zurbau, Andreea
Jain, Manish
Gote, Manoj
Bhaduri, Anirban
Mullick, Ashim
author_sort Shah, Priyali
collection PubMed
description Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present randomized, controlled, cross-over study was conducted in 3 phases to explore GR and IR to ingestion of FOSS, when replaced by/added to available-carbohydrates (avCHO) among 25 healthy adults (40 ± 14years). In each phase GR and IR elicited by 3–4 test-meals were measured among the fasted recruited subjects. The interventional test meals were as follows: Phase-1, water alone or 10g FOSS or 10g Dextrose in 250ml water; Phase-2, 250ml water containing Dextrose:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15; Phase-3 portions of white-bread (WB) containing avCHO:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15. Blood samples (finger prick method) were collected at fasting and 15, 30, 45, 60, 90 and 120 min after start of test meal ingestion. Plasma glucose and serum insulin were analyzed utilizing standard methods. The primary endpoint was differences in glucose IAUC. All subjects provided their written consent to participate in the study (ClinicalTrials.gov: NCT03755232). The results demonstrated that FOSS, when consumed alone, showed no raise in glycaemia or insulinemia and was statistically equivalent to response of water alone. GR and IR elicited by dextrose:FOSS and WB:FOSS test-meals of Phase 2 and Phase 3, were statistically equivalent to the respective test-meals without FOSS. Result of the 3 phases support the hypothesis that FOSS is resistant to breakdown and is indigestible in the human small-intestine, and therefore can be classified as an unavailable carbohydrate that does not raise post prandial blood glucose or insulin. FOSS, being sweet to taste, may be an acceptable sugar replacer in beverages without compromising their taste and sensory qualities.
format Online
Article
Text
id pubmed-8102419
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81024192021-05-14 Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial Shah, Priyali Wolever, Thomas MS. Jenkins, Alexandra L. Ezatagha, Adish Campbell, Janice Zurbau, Andreea Jain, Manish Gote, Manoj Bhaduri, Anirban Mullick, Ashim Heliyon Research Article Short chain fructo-oligosaccharides (scFOS) are well-recognized prebiotic fibers. Fossence™ (FOSS) is a scFOS that has been produced from sucrose via a proprietary fermentation process and has not been tested for its digestibility or glucose/insulin response (GR and IR, respectively). The present randomized, controlled, cross-over study was conducted in 3 phases to explore GR and IR to ingestion of FOSS, when replaced by/added to available-carbohydrates (avCHO) among 25 healthy adults (40 ± 14years). In each phase GR and IR elicited by 3–4 test-meals were measured among the fasted recruited subjects. The interventional test meals were as follows: Phase-1, water alone or 10g FOSS or 10g Dextrose in 250ml water; Phase-2, 250ml water containing Dextrose:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15; Phase-3 portions of white-bread (WB) containing avCHO:FOSS (g:g) in the content as 50:0 or 50:15 or 35:0 or 35:15. Blood samples (finger prick method) were collected at fasting and 15, 30, 45, 60, 90 and 120 min after start of test meal ingestion. Plasma glucose and serum insulin were analyzed utilizing standard methods. The primary endpoint was differences in glucose IAUC. All subjects provided their written consent to participate in the study (ClinicalTrials.gov: NCT03755232). The results demonstrated that FOSS, when consumed alone, showed no raise in glycaemia or insulinemia and was statistically equivalent to response of water alone. GR and IR elicited by dextrose:FOSS and WB:FOSS test-meals of Phase 2 and Phase 3, were statistically equivalent to the respective test-meals without FOSS. Result of the 3 phases support the hypothesis that FOSS is resistant to breakdown and is indigestible in the human small-intestine, and therefore can be classified as an unavailable carbohydrate that does not raise post prandial blood glucose or insulin. FOSS, being sweet to taste, may be an acceptable sugar replacer in beverages without compromising their taste and sensory qualities. Elsevier 2021-04-28 /pmc/articles/PMC8102419/ /pubmed/33997376 http://dx.doi.org/10.1016/j.heliyon.2021.e06805 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Shah, Priyali
Wolever, Thomas MS.
Jenkins, Alexandra L.
Ezatagha, Adish
Campbell, Janice
Zurbau, Andreea
Jain, Manish
Gote, Manoj
Bhaduri, Anirban
Mullick, Ashim
Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title_full Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title_fullStr Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title_full_unstemmed Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title_short Acute glycemic and insulin response of Fossence™ alone, or when substituted or added to a carbohydrate challenge: A three-phase, acute, randomized, cross-over, double blind clinical trial
title_sort acute glycemic and insulin response of fossence™ alone, or when substituted or added to a carbohydrate challenge: a three-phase, acute, randomized, cross-over, double blind clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102419/
https://www.ncbi.nlm.nih.gov/pubmed/33997376
http://dx.doi.org/10.1016/j.heliyon.2021.e06805
work_keys_str_mv AT shahpriyali acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT woleverthomasms acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT jenkinsalexandral acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT ezataghaadish acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT campbelljanice acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT zurbauandreea acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT jainmanish acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT gotemanoj acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT bhadurianirban acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial
AT mullickashim acuteglycemicandinsulinresponseoffossencealoneorwhensubstitutedoraddedtoacarbohydratechallengeathreephaseacuterandomizedcrossoverdoubleblindclinicaltrial